April 10, 2024

C4U and Sumitomo Pharma have entered into a license agreement, granting Sumitomo Pharma the right to develop and market regenerative medicine product for central nervous system diseases utilizing CRISPR-Cas3 technology.
C4U and Sumitomo Pharma have conducted three collaborative research projects since 2021, one of which resulted in the conclusion of this agreement.

April 3, 2024

The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” was issued by European Patent Office.
Patent registration number: No. 3636753

February 21, 2024

The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” was issued by Japan Patent Office.
Patent registration number: No. 7430358

February 14, 2024

The patent for the invention, “METHOD FOR PRODUCING KNOCK-IN CELL”, was issued by Japan Patent Office.
Patent registration number: No. 7426120

December 14, 2023

C4U and Celaid Therapeutics have executed a collaborative research agreement for a hematopoietic stem cell gene therapy product.